Acadia Pharma (ACAD) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 8, 2022 4:05 PM EDT- 2Q22 net sales of $134.6 million, a 17% increase over 2Q21
- NDA submitted for trofinetide for the treatment of Rett syndrome
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
In the second quarter of 2022, NUPLAZID net sales increased 17% year-over-year, said Steve Davis, Chief Executive Officer. Last month, we submitted an NDA for our second potential commercial product, trofinetide which would be the first FDA-approved treatment for Rett syndrome. Together with a strong... More
